RxDoctor Payments DataLook up a doctor →

Rodney Johnson, MD

Allergy & Immunology · Dublin, GANPI 1992828289

Payments from drug & device makers

$22,332in general payments, 2019–2025

Across 472 payments — averaging $47.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$14K
  • GSK$1K
  • Sanofi$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Genentech USA, Inc.$670
  • Grifols USA, LLC$582
  • plus $3K from 23 others

What the payments were for

  • Consulting fees$740%
  • Speaking & faculty fees$11,65052%
  • Travel & lodging$2961%
  • Food & beverage$10,07645%
  • Education$2361%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,332 in reported general payments places this provider in the 80th percentile of 107 allergy & immunology providers in Georgia.

See all allergy & immunology providers in Georgia

Medicare billing

Part B allowed, 2024
$669,758
Medicare patients
154
Services billed
31,949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab58$221,667
Dupixent SyringeDupilumab47$190,719
XolairOmalizumab21$82,060
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$65,080
NucalaMepolizumab11$42,572
Breo ElliptaFluticasone/Vilanterol18$11,549
Epinephrine40$9,085
SymbicortBudesonide/Formoterol Fumarate22$4,619
Azelastine Hcl130$3,572
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,976
Ipratropium Bromide125$2,786
Fluticasone Propionate130$1,823
Albuterol Sulfate HfaAlbuterol Sulfate32$896
Montelukast Sodium93$695
Clobetasol Propionate22$592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta$1,280$119,201113 claims
Hikma Pharmaceuticals USAEpinephrine$69$9,08540 claims
AstraZenecaSymbicort$14,083$4,61922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 107 allergy & immunology providers in Georgia.

Other allergy & immunology in Dublin

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →